Advertisement

Archives of Pharmacal Research

, Volume 23, Issue 1, pp 46–49 | Cite as

Antifungal activity of magnolol and honokiol

  • Kyu Ho Bang
  • Yoon Kwan Kim
  • Byung Sun Min
  • Min Kyun Na
  • Young Ha Rhee
  • Jong Pill Lee
  • Ki Hwan BaeEmail author
Research Articles Medicinal Chemistry & Natural Products

Abstract

Two neolignan compounds, magnolol (5,5′-diallyl-2,2′-dihydroxybiphenyl,1) and honokiol (5,5′-diallyl-2,4′-dihydroxybiphenyl,2), were isolated from the stem bark ofMagnolia obovata and evaluated for antifungal activity against various human pathogenic fungi. Compound1 and2 showed significant inhibitory activities againstTrichophyton mentagrophytes, Microsporium gypseum, Epidermophyton floccosum, Aspergillus niger, Cryptococcus neoformans, andCandida albicans with minimum inhibitory concentrations (MIC) in a range of 25–100 μg/ml. Therefore, compound1 and2 could be used as lead compounds for the development of novel antifungal agents.

Key words

Magnolol Honokiol Human pathogenic fungi Magnolia obovata Magnoliaceae 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bae, K., Yoo, B., Lee, M. and Seo, W., Antimicrobial activities of hydroxybiphenyl derivatives (I), Antibacterial activities and HPLC determination of magnolol and honokiol.Arch. Pharm. Res., 8, 85–89 (1985).CrossRefGoogle Scholar
  2. Chang, B. S., Lee, Y. M., Ku, Y., Bae, K. H. and Chung, C. P., Antimicrobial activity of magnolol and honokiol against periodontopathic microorganisms.Planta Medica, 64, 367–369 (1998).PubMedCrossRefGoogle Scholar
  3. Fukuyama, Y., Otoshi, Y., Miyoshi, K., Hasegawa, N., Kan, Y. and Komada, M., Structure of magnolianin, A novel triligna possessing potent 5-lipoxygenase inhibitory activity.Tetrahedron Lett., 34, 1051–1054 (1993).CrossRefGoogle Scholar
  4. Grayer, R. J. and Harbone, J. B. A., Survey of antifungal compounds from higher plants.Phytochemistry, 37, 19–42 (1994).CrossRefGoogle Scholar
  5. Huang, K. C.,The Pharmacology of Chinese Herb’s. CRE Press, Ann Arbor, p. 173, 1993.Google Scholar
  6. Kijjoa, A., Pinto, M. M. M., Tantisewie, B. and Herz, W., A biphenyl type neolignan and biphenyl ether fromMagnolia henryi.Phytochemistry, 28, 1284–1286 (1989).CrossRefGoogle Scholar
  7. Kwon, B. M., Kim, M. K., Lee, S. H., Kim, J. A., Lee, I. L., Kim, Y. K. and Bok, S. H., Acyl-CoA: Cholesterol acyltransferase inhibitors fromMagnolia obovata.Planta Medica, 63, 550–551 (1997).PubMedCrossRefGoogle Scholar
  8. Mattew, P. S., Omar, P. S. and Jerome, L. S., Systemic drugs in the treatment of dermatophytosis.Int. J. Dermatology, 32, 16–20 (1993).CrossRefGoogle Scholar
  9. Moore, G. S. and Jaciow, D. W.,Mycology for the clinical laboratory. Reston Publishing, Virginia, pp. 262–266 (1979).Google Scholar
  10. Namba, T., Tsunezuka, M., Bae, K. H. and Hattori, M., Studies on dental caries prevention by traditional Chinese medicines (part I), Screening of crude drugs for antibacterial action againstStreptococcus mutans.Shoyaku Zasshi, 35, 295–302 (1981).Google Scholar
  11. Namba, T., Tsunezuka, M. and Hattori, M., Dental caries by traditional Chinese medicines (part II), Potent antibacterial action of Magnoliae Cortex extracts againstStreptococcus mutans.Planta Medica, 44, 100–106 (1982).PubMedCrossRefGoogle Scholar
  12. Nitao, J. K., Nair, M. G., Thorogood, D. L., Johnson, K. S. and Scriber, J. M., Bioactive neolignans from the leaves ofMagnolia virginiana.Phytochemistry, 30, 2193–2195 (1991).CrossRefGoogle Scholar
  13. Ormsby, O. S. and Montgomery, M.,Disease of the skin. Lea & Fibiger, Philadelphia, p. 1128, 1954.Google Scholar
  14. Seo, W. J., Koo, S. H. and Bae, K. H., Antimicrobial activity of hydroxybiphenyl derivatives.Arch. Pharm. Res., 9, 127–130 (1986).CrossRefGoogle Scholar
  15. Yahara, S., Nishiyori, T., Kohda, A., Nohara, T. and Nishioka I., Isolation and characterization of phenolic compounds from Magnoliae Cortex produced in China.Chem. Pharm. Bull., 39, 2024–2036 (1991).Google Scholar
  16. Yamaguchi, H., Antifungal agents-recent trends in development and progress in research of action mechanism.Jap. J. Clinic. Med., 49, 2176–2185 (1990).Google Scholar

Copyright information

© The Pharmaceutical Society of Korea 1999

Authors and Affiliations

  • Kyu Ho Bang
    • 1
    • 3
  • Yoon Kwan Kim
    • 1
  • Byung Sun Min
    • 2
  • Min Kyun Na
    • 2
  • Young Ha Rhee
    • 3
  • Jong Pill Lee
    • 4
  • Ki Hwan Bae
    • 2
    Email author
  1. 1.R & D CenterKolon Pharmaceutical Inc.TaejonKorea
  2. 2.College of PharmacyChungnam National UniversityTaejonKorea
  3. 3.Department of MicrobiologyChungnam National UniversityTaejonKorea
  4. 4.Natural Medicinal Products DivisionKorea Food & Drug AdministrationSeoulKorea

Personalised recommendations